Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals

By: via Benzinga
In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated a Neutral rating and $8.00 price target on Ariad ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.